title: Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation.
abstract: BACKGROUND
  Acute renal failure (ARF) in critically ill patients is associated with a high mortality rate. Continuous renal replacement therapy (CRRT) is now widely used for the treatment of ARF in these critically ill patients. We retrospectively analyzed the role of CRRT as a prognostic parameter in patients receiving a cadaveric liver graft in 1998.
  
  
  METHODS
  We reviewed the patient records of all adult recipients of a cadaveric liver graft (N = 54) in 1998 and compared those who underwent CRRT treatment (N = 19) to those without CRRT treatment (N = 35).
  
  
  RESULTS
  Mortality was high in the continuous venovenous hemodialysis (CVVHD) group (58%). At the time of transplantation, creatinine (1.7+/-0.4 vs. 1.0+/-0.1 mg/dl), blood urea nitrogen (40+/-13 vs. 22+/-3 mg/dl), aspartate aminotransferase (ASAT; 585+/-420 vs. 242+/-97 U/liter), and bilirubin (11.6+/-4.1 vs. 6.5+/-1.9 mg/dl) were higher in the CVVHD group than in controls, whereas hemoglobin (10.3+/-0.6 vs. 10.8+/-0.4 g/dl), white blood cells (6.3+/-0.6 vs. 7.0+/-0.8/nl), and thrombocytes (110+/-18 vs. 90+/-10/nl) were similar. After transplantation, liver graft function was impaired in the CVVHD group as compared with controls.
  
  
  CONCLUSIONS
  The necessity for CRRT in patients after liver transplantation correlates with a high risk of death. Thus, more efforts have to be made to prevent renal failure in patients after liver transplantation.
authors.affiliation: Department of Nephrology, U niversitätsklinikum Essen, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Lütkes
authors.forename: J
authors.initials: J
authors.lastname: Lutz
authors.forename: J
authors.initials: J
authors.lastname: Loock
authors.forename: A
authors.initials: A
authors.lastname: Daul
authors.forename: C
authors.initials: C
authors.lastname: Broelsch
authors.forename: T
authors.initials: T
authors.lastname: Philipp
authors.forename: U
authors.initials: U
authors.lastname: Heemann
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D015415:Biomarkers; D015992:Body Mass Index; D016638:Critical Illness / Q000628:therapy*; D005260:Female; D006085:Graft Survival; D006440:Hemofiltration; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D015415:Biomarkers